Concepedia

Author

Yaël C. Cohen

Tel Aviv UniversityORCID

Also Known As

A. Joseph Foldes, Y Cohen, Y. C. COHEN, Y. C. Cohen, Y. Cohen, Y.C. Cohen, YAEL COHEN, Yael C Cohen, Yael C. Cohen, Yael Chava Cohen

327

Publications

4.6K

Citations

31

H-Index

95

Concepts

All Affiliations

Tel Aviv UniversityTel Aviv Sourasky Medical CenterSheba Medical CenterHadassah Medical CenterJanssen (United States)
YC

About

Yaël C. Cohen is an author at Tel Aviv University specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

27

1K

2

Health Sciences

8

8

259

3

Education

1

1

11

4

Public Health

1

1

27

5

Allergy

1

1

84

Yaël C. Cohen

×

73

Publications

4.2K

Citations

31

H-Index

YearCitations

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong,

New England Journal of Medicine

2023

615

The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts

Yaël C. Cohen, Benjamin Djulbegović, Orna Shamai‐Lubovitz,

Archives of Internal Medicine

2000

422

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

‬‬‬‬Abdulla Watad, Gabriele De Marco, Hussein Mahajna,

Vaccines

2021

364

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Guy Ledergor, Assaf Weiner, Mor Zada,

Nature Medicine

2018

271

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Yaël C. Cohen, Mor Zada, Shuang-Yin Wang,

Nature Medicine

2021

229

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Adam D. Cohen, María‐Victoria Mateos, Yaël C. Cohen,

Blood

2022

182

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Chava Perry, Efrat Luttwak, R. Balaban,

Blood Advances

2021

166

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Ola Landgren, Ajai Chari, Yaël C. Cohen,

Leukemia

2020

91

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Yaël C. Cohen, Daniel Morillo, Moshe E. Gatt,

Journal of Clinical Oncology

2023

84

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z. Usmani, Thierry Façon, Vânia Hungria,

Nature Medicine

2025

74

Page 1